Log In
Print this Print this

Enhanced TCR Therapy

  Manage Alerts
Collapse Summary General Information
Company Adaptimmune Therapeutics plc
DescriptionT cells genetically modified to express T cell receptors (TCR) targeting specific cancer antigens
Molecular Target Cancer/testis antigen 1B (CTAG1B) (NY-ESO-1) ; Cancer/testis antigen 2 (CTAG2) (LAGE1) (NY-ESO-2)
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationOvarian cancer
Indication DetailsTreat ovarian cancer
Regulatory Designation


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today